Cargando…
Large-scale transcriptome analysis identified RNA methylation regulators as novel prognostic signatures for lung adenocarcinoma
BACKGROUND: The abnormal expression of genes is an essential factor affecting the prognosis of cancer. RNA modification is a way of regulating post-transcriptional levels, including m(6)A, m(5)C, m(1)A RNA methylation. Studies have found that RNA methylation regulates tumorigenesis development and s...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333141/ https://www.ncbi.nlm.nih.gov/pubmed/32647676 http://dx.doi.org/10.21037/atm-20-3744 |
_version_ | 1783553688989597696 |
---|---|
author | Sun, Lei Liu, Wen-Ke Du, Xiao-Wei Liu, Xiang-Li Li, Gao Yao, Yao Han, Tao Li, Wen-Ya Gu, Jia |
author_facet | Sun, Lei Liu, Wen-Ke Du, Xiao-Wei Liu, Xiang-Li Li, Gao Yao, Yao Han, Tao Li, Wen-Ya Gu, Jia |
author_sort | Sun, Lei |
collection | PubMed |
description | BACKGROUND: The abnormal expression of genes is an essential factor affecting the prognosis of cancer. RNA modification is a way of regulating post-transcriptional levels, including m(6)A, m(5)C, m(1)A RNA methylation. Studies have found that RNA methylation regulates tumorigenesis development and stem cell regeneration. However, there are few studies on lung adenocarcinoma. This study aims to explore the clinical value of RNA methylation for lung adenocarcinoma. METHODS: We summarized thirty-one RNA methylation regulators. The training set was obtained from The Cancer Genome Atlas (TCGA) database, and the test set was obtained from the Gene Expression Omnibus (GEO) database. The Wilcoxon test was used to analyze the expression of RNA methylation regulators. We constructed tumor subgroup models and risk models based on the expression of those regulators. Principal component analysis (PCA) and the receiver operating characteristic (ROC) confirmed the accuracy of the models. Real-time polymerase chain reaction (PCR) validates the results in vitro. RESULTS: Most RNA methylation regulators had distinct expressions in tumor tissues and adjacent tissues (P<0.05). All the models showed high predictive performance (AUC: 0.65–0.82), and the five-year survival of patients in each group was statistically different (P<0.05). The patients in the high-risk group were more likely to have a higher stage, more lymph node metastases, and distant metastases, showing a poor clinical outcome. Patients with high expression of NOP2 or HNRNP were more likely to have a poorly differentiated in vitro experiment. CONCLUSIONS: With our study, we found that the expressions of most RNA methylation regulators were significantly different in cancer and para-cancerous tissues. Different molecular phenotypes constructed by RNA methylation regulators can be independent risk factors for the prognosis of lung adenocarcinoma. Our study demonstrates the critical role of RNA methylation in lung adenocarcinoma, and it is expected to supply a reference for the prognostic stratification and treatment strategy development of lung adenocarcinoma. |
format | Online Article Text |
id | pubmed-7333141 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-73331412020-07-08 Large-scale transcriptome analysis identified RNA methylation regulators as novel prognostic signatures for lung adenocarcinoma Sun, Lei Liu, Wen-Ke Du, Xiao-Wei Liu, Xiang-Li Li, Gao Yao, Yao Han, Tao Li, Wen-Ya Gu, Jia Ann Transl Med Original Article BACKGROUND: The abnormal expression of genes is an essential factor affecting the prognosis of cancer. RNA modification is a way of regulating post-transcriptional levels, including m(6)A, m(5)C, m(1)A RNA methylation. Studies have found that RNA methylation regulates tumorigenesis development and stem cell regeneration. However, there are few studies on lung adenocarcinoma. This study aims to explore the clinical value of RNA methylation for lung adenocarcinoma. METHODS: We summarized thirty-one RNA methylation regulators. The training set was obtained from The Cancer Genome Atlas (TCGA) database, and the test set was obtained from the Gene Expression Omnibus (GEO) database. The Wilcoxon test was used to analyze the expression of RNA methylation regulators. We constructed tumor subgroup models and risk models based on the expression of those regulators. Principal component analysis (PCA) and the receiver operating characteristic (ROC) confirmed the accuracy of the models. Real-time polymerase chain reaction (PCR) validates the results in vitro. RESULTS: Most RNA methylation regulators had distinct expressions in tumor tissues and adjacent tissues (P<0.05). All the models showed high predictive performance (AUC: 0.65–0.82), and the five-year survival of patients in each group was statistically different (P<0.05). The patients in the high-risk group were more likely to have a higher stage, more lymph node metastases, and distant metastases, showing a poor clinical outcome. Patients with high expression of NOP2 or HNRNP were more likely to have a poorly differentiated in vitro experiment. CONCLUSIONS: With our study, we found that the expressions of most RNA methylation regulators were significantly different in cancer and para-cancerous tissues. Different molecular phenotypes constructed by RNA methylation regulators can be independent risk factors for the prognosis of lung adenocarcinoma. Our study demonstrates the critical role of RNA methylation in lung adenocarcinoma, and it is expected to supply a reference for the prognostic stratification and treatment strategy development of lung adenocarcinoma. AME Publishing Company 2020-06 /pmc/articles/PMC7333141/ /pubmed/32647676 http://dx.doi.org/10.21037/atm-20-3744 Text en 2020 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article Sun, Lei Liu, Wen-Ke Du, Xiao-Wei Liu, Xiang-Li Li, Gao Yao, Yao Han, Tao Li, Wen-Ya Gu, Jia Large-scale transcriptome analysis identified RNA methylation regulators as novel prognostic signatures for lung adenocarcinoma |
title | Large-scale transcriptome analysis identified RNA methylation regulators as novel prognostic signatures for lung adenocarcinoma |
title_full | Large-scale transcriptome analysis identified RNA methylation regulators as novel prognostic signatures for lung adenocarcinoma |
title_fullStr | Large-scale transcriptome analysis identified RNA methylation regulators as novel prognostic signatures for lung adenocarcinoma |
title_full_unstemmed | Large-scale transcriptome analysis identified RNA methylation regulators as novel prognostic signatures for lung adenocarcinoma |
title_short | Large-scale transcriptome analysis identified RNA methylation regulators as novel prognostic signatures for lung adenocarcinoma |
title_sort | large-scale transcriptome analysis identified rna methylation regulators as novel prognostic signatures for lung adenocarcinoma |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333141/ https://www.ncbi.nlm.nih.gov/pubmed/32647676 http://dx.doi.org/10.21037/atm-20-3744 |
work_keys_str_mv | AT sunlei largescaletranscriptomeanalysisidentifiedrnamethylationregulatorsasnovelprognosticsignaturesforlungadenocarcinoma AT liuwenke largescaletranscriptomeanalysisidentifiedrnamethylationregulatorsasnovelprognosticsignaturesforlungadenocarcinoma AT duxiaowei largescaletranscriptomeanalysisidentifiedrnamethylationregulatorsasnovelprognosticsignaturesforlungadenocarcinoma AT liuxiangli largescaletranscriptomeanalysisidentifiedrnamethylationregulatorsasnovelprognosticsignaturesforlungadenocarcinoma AT ligao largescaletranscriptomeanalysisidentifiedrnamethylationregulatorsasnovelprognosticsignaturesforlungadenocarcinoma AT yaoyao largescaletranscriptomeanalysisidentifiedrnamethylationregulatorsasnovelprognosticsignaturesforlungadenocarcinoma AT hantao largescaletranscriptomeanalysisidentifiedrnamethylationregulatorsasnovelprognosticsignaturesforlungadenocarcinoma AT liwenya largescaletranscriptomeanalysisidentifiedrnamethylationregulatorsasnovelprognosticsignaturesforlungadenocarcinoma AT gujia largescaletranscriptomeanalysisidentifiedrnamethylationregulatorsasnovelprognosticsignaturesforlungadenocarcinoma |